The estimated Net Worth of Emily Gottschalk is at least $141 Тысяча dollars as of 15 July 2021. Ms. Gottschalk owns over 20,065 units of Anixa Biosciences stock worth over $141,105 and over the last 5 years she sold ANIX stock worth over $0. In addition, she makes $0 as Independent Director at Anixa Biosciences.
Sign up
Ms. Gottschalk ANIX stock SEC Form 4 insiders trading
Emily has made over 3 trades of the Anixa Biosciences stock since 2021, according to the Form 4 filled with the SEC. Most recently she bought 20,065 units of ANIX stock worth $79,457 on 15 July 2021.
The largest trade she's ever made was buying 20,065 units of Anixa Biosciences stock on 15 July 2021 worth over $79,457. On average, Emily trades about 5,074 units every 12 days since 2019. As of 15 July 2021 she still owns at least 45,665 units of Anixa Biosciences stock.
You can see the complete history of Ms. Gottschalk stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Emily Gottschalk biography
Emily Gottschalk serves as Independent Director of the Company. She is an experienced marketer with over 30 years of developing products for the consumer marketplace. She has been the CEO of The Garr Group, Inc. since 1997, a diverse entertainment and new product development company that she founded that sells entertainment and general merchandise to the mass, specialty and on-line market. Ms. Gottschalk co-founded IdeationUSA, LLC in 2017, a product development company focused on bringing innovative electronics to the consumer market. IdeationUSA identifies “white space” opportunities in the marketplace and defines and develops products that uniquely touch consumers lives. Ideation is equally focused on brick and mortar, on-line and emerging distribution channels. Previously, she was Marketing Director of Zany Brainy, a children’s educational toy store that she launched. Since 1997, Ms. Gottschalk’s companies have produced over 150 million CD’s/DVD’s to the US retail market, developed a proprietary Android tablet called “RealPad, by AARP” with Intel and has created private label brands across the home and craft market. She is a graduate of Cornell University’s School of Hotel Administration and serves on the board of several philanthropic organizations.
How old is Emily Gottschalk?
Emily Gottschalk is 59, she's been the Independent Director of Anixa Biosciences since 2019. There are 4 older and 6 younger executives at Anixa Biosciences. The oldest executive at Anixa Biosciences, Inc. is Lewis Titterton, 75, who is the Lead Independent Director.
What's Emily Gottschalk's mailing address?
Emily's mailing address filed with the SEC is C/O ANIXA BIOSCIENCES, INC., 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE,, CA, 95118.
Insiders trading at Anixa Biosciences
Over the last 6 years, insiders at Anixa Biosciences have traded over $0 worth of Anixa Biosciences stock and bought 834,156 units worth $2,822,805 . The most active insiders traders include Amit Kumar, Lewis H Jr Titterton и Arnold M Baskies. On average, Anixa Biosciences executives and independent directors trade stock every 31 days with the average trade being worth of $78,894. The most recent stock trade was executed by Lewis H Jr Titterton on 30 July 2024, trading 27,226 units of ANIX stock currently worth $84,128.
What does Anixa Biosciences do?
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
What does Anixa Biosciences's logo look like?
Complete history of Ms. Gottschalk stock trades at Anixa Biosciences
Anixa Biosciences executives and stock owners
Anixa Biosciences executives and other stock owners filed with the SEC include:
-
Dr. Amit Kumar Ph.D.,
Chairman, Pres & CEO -
Amit Kumar,
Chairman of the Board, President, Chief Executive Officer -
Michael J. Catelani CPA, MBA,
Pres, COO, CFO & Corp. Sec. -
Michael J. Catelani,
COO, CFO & Corp. Sec. -
Michael Catelani,
Chief Financial Officer, Chief Operating Officer -
Lewis Titterton,
Lead Independent Director -
John Monahan,
Independent Director -
Emily Gottschalk,
Independent Director -
David Cavalier,
Independent Director -
Arnold Baskies,
Independent Director -
Thomas Schlumpberger,
Executive Vice President -
Dr. Pamela D. Garzone Ph.D.,
Chief Devel. Officer -
John Roop,
Sr. VP of Engineering